Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Free Cash Flow: 2018-2024

Historic Free Cash Flow for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$201.0 million.

  • Allogene Therapeutics' Free Cash Flow rose 32.97% to -$29.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$159.0 million, marking a year-over-year increase of 27.05%. This contributed to the annual value of -$201.0 million for FY2024, which is 15.99% up from last year.
  • Per Allogene Therapeutics' latest filing, its Free Cash Flow stood at -$201.0 million for FY2024, which was up 15.99% from -$239.2 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Free Cash Flow registered a high of -$181.1 million during FY2020, and its lowest value of -$239.2 million during FY2023.
  • Over the past 3 years, Allogene Therapeutics' median Free Cash Flow value was -$225.7 million (recorded in 2022), while the average stood at -$222.0 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first decreased by 13.92% in 2021, then climbed by 15.99% in 2024.
  • Over the past 5 years, Allogene Therapeutics' Free Cash Flow (Yearly) stood at -$181.1 million in 2020, then dropped by 13.92% to -$206.3 million in 2021, then decreased by 9.43% to -$225.7 million in 2022, then dropped by 6.00% to -$239.2 million in 2023, then grew by 15.99% to -$201.0 million in 2024.